During the last two decades, the therapeutic landscape for EGFRMT NSCLC patients has profoundly changed with the discovery that NSCLCs with EGFR mutations, either small, in-frame deletions or amino acid substitutions clustered around the ATP-binding pocket of the EGFR tyrosine kinase domain (10), show meaningful responses to EGFR tyrosine kinase inhibitors (TKIs), including gefitinib, erlotinib, and afatinib (11, 12). This evidence concerns the gene EGFR and non-small cell lung carcinoma.